Find Deupirfenidone manufacturers, exporters & distributors on PharmaCompass

Deupirfenidone

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

$ API Reference Price

$ API Reference Price

DEVELOPMENTS

9 Drugs in Development

9 Drugs in Development

DIGITAL CONTENT

9 NEWS #PharmaBuzz

media
9 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1qc36bhi6s, Lyt-100, 1093951-85-9, 2(1h)-pyridinone, 5-(methyl-d3)-1-phenyl-, 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one, Deupirfenidone [usan]

Molecular Formula

C₁₂H₁₁NO

Molecular Weight

188.24 g/mol

InChI Key

ISWRGOKTTBVCFA-FIBGUPNXSA-N

FDA UNII

1QC36BHI6S

Deupirfenidone is an orally bioavailable and deuterated form of the synthetic antifibrotic agent pirfenidone, with potential anti-inflammatory and anti-fibrotic activities. Upon administration, deupirfenidone inhibits a variety of pro-inflammatory mediators, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a) and transforming growth factor-beta (TGF-b). This may reduce fibrosis, inflammation and infection, and may repair the impaired lymphatic flow, decrease lymphedema and restore lymphatic function. In the lungs, deupirfenidone may abrogate impaired lung function, lymphoedema and pulmonary fibrosis.

1 2D Structure

Deupirfenidone

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-phenyl-5-(trideuteriomethyl)pyridin-2-one

2.1.2 InChI

InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3/i1D3

2.1.3 InChI Key

ISWRGOKTTBVCFA-FIBGUPNXSA-N

2.1.4 Canonical SMILES

CC1=CN(C(=O)C=C1)C2=CC=CC=C2

2.1.5 Isomeric SMILES

[2H]C([2H])([2H])C1=CN(C(=O)C=C1)C2=CC=CC=C2

2.2 Other Identifiers

2.2.1 UNII

1QC36BHI6S

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one

2. 5-methyl-1-phenyl-2-(1h)-pyridone

3. Deskar

4. Esbriet

5. Pirfenidone

2.3.2 Depositor-Supplied Synonyms

1. 1qc36bhi6s

2. Lyt-100

3. 1093951-85-9

4. 2(1h)-pyridinone, 5-(methyl-d3)-1-phenyl-

5. 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one

6. Deupirfenidone [usan]

7. Unii-1qc36bhi6s

8. Lyt100

9. Schembl4059454

10. Deupirfenidone [who-dd]

11. Sd-560

12. Who 12460

13. At18410

2.4 Create Date

2009-02-09

3 Chemical and Physical Properties

Molecular Formula	C₁₂H₁₁NO
Molecular Weight	188.24 g/mol
XLogP3	1.9
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	1
Rotatable Bond Count	1
Exact Mass	188.102894212 g/mol
Monoisotopic Mass	188.102894212 g/mol
Topological Polar Surface Area	20.3 Å²
Heavy Atom Count	14
Formal Charge	0
Complexity	285
Isotope Atom Count	3
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Analgesics

Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)

Anti-Inflammatory Agents, Non-Steroidal

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Drugs in Development